KT-621 — Topline data
Late 2026
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026Source filing
KYMR biotech catalysts & pipeline
KYMERA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
KT-579 — Clinical data readout
Q4 2026
Enrollment is ongoing in the KT-579 Phase 1 clinical trial in healthy volunteers , with data expected in the fourth quarter of 2026.Source filing
KT-200 — IND submission
2027
Gilead intends to progress the program into IND-enabling studies to support an IND filing in 2027.Source filing
KT-621 — Clinical data readout
late 2027
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027Source filing